Trial · NCT07899047
Albumin-Bound Paclitaxel (Ⅱ) in Patients With Advanced Breast Cancer
NCT07899047, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Albumin-Bound Paclitaxel (Ⅱ) in Patients With Advanced Breast Cancer. Trials, record NCT07899047. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07899047
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Albumin-Bound Paclitaxel (Ⅱ) in Patients With Advanced Breast Cancer
- NCT number
- NCT07899047
- Status
- Not yet recruiting
- Enrollment
- 1,372 participants, estimated
- Lead sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Conditions
- Breast Cancer, HER2-negative Breast Cancer, Advanced Breast Cancer
- Interventions
- Experimental Group, control group
- First posted
- 2026-10-27
- Last updated
- 2026-10-27
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Survival (OS) | 42 months | Time from the participant's first study-drug administration to death from any cause. |
| Secondary | Objective Response Rate (ORR) | 42 months | Proportion of participants achieving best overall tumour response of complete response (CR) or partial response (PR), assessed per RECIST version 1.1. |
| Secondary | Disease Control Rate (DCR) | 42 months | Proportion of participants achieving best overall tumour response of CR, PR, or stable disease (SD), assessed per RECIST version 1.1. |
| Secondary | Progression-Free Survival (PFS) | 42 months | Time from the participant's first study-drug administration to tumour progression or death from any cause, whichever occurs first. |
| Secondary | Safety | 42 months | Incidence and severity of adverse events occurring throughout the study period. |
| Secondary | Incidence of rash within the first two cycles and over all treatment cycles | 42 months | Incidence and severity of rash events occurring within the specified treatment periods. |
| Secondary | Health-related quality of life | 42 months | EQ-5D-5L questionnaire scores collected at each study visit, which will be converted into health utility values for the Chinese general population. |
| Secondary | Time from preparation start to complete dispersion | 42 months | At Cycle 1, when preparing the first vial of study drug. |
| Secondary | Health-economic outcomes | 42 months | Health-economic outcomes include real-world direct medical costs and QALYs derived from EQ-5D-5L. Cost-effectiveness will be evaluated by calculating the ICER to compare the two albumin-bound paclitaxel regimens. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07899047
GET https://conductscience.org/api/trials/v1/NCT07899047/registered